NEW YORK, NY - July 16, 2012 (Investorideas.com newswire) -
InvestorIdeas.com, an investor research portal specializing in sector
research including biotech and pharma stocks, issues a Q&A snapshot
of two biotech companies taking aim at aggressive forms of cancer; Roche
(SIX:RO) (
ROG.VX) (
RHHBY) (
RHHBY) with its Herceptin® cancer drug and Sunshine Biopharma Inc. (
SBFM) with its lead compound, Adva-27a.
The interview(s) gives investors insight into how a small biotech
company, Sunshine Biopharma, plans to target the cancer drug market of
the future with its
technology
and collaborations and the historical path of the largest biotech
company in the world bringing Herceptin to market, reaching
sales of over $5 billion in 2010.
Roche (
SIX: RO, ROG; OTCQX: RHHBY)
/Genetech’s Herceptin:
Q: Investorideas.com staff:
When was the licensing agreement put in place with Genentech and Roche for Herceptin®?
A: Nina Goworek, Investor Relations Officer for Roche
Genentech and Roche signed a licensing agreement giving Roche
exclusive marketing rights for Herceptin outside of the US in July 1998
Q: Investorideas.com staff:
What other cancers are targeted with Herceptin® other than HER2-positive breast cancer and what FDA approvals are in place?
A: Nina Goworek, Investor Relations Officer for Roche
In the US:
September 1998 - Herceptin is approved for 1st-line Her2 positive
metastatic breast cancer in combination with chemotherapy (paclitaxel)
and also approved as a medicine to be used alone for women who had
received prior chemotherapy (second- and third-line treatment),
November 2006 - Herceptin is approved for adjuvant or early stage
HER2 positive breast cancer when given with chemotherapy (doxorubicin,
cyclophosphamide and paclitaxel), a combination called AC-TH
January 2008 - approved as a stand-alone medicine following anthracycline-based chemotherapy
May 2008 - Herceptin and chemotherapy (docetaxel and carboplatin),
known as TCH, was approved; Another AC-TH combination, comprised of
Herceptin, doxorubicin, cyclophosphamide and docetaxel, was also
approved
October 2010 - Herceptin is approved in combination with cisplatin
and capecitabine or 5-fluorouracil, for the treatment of patients with
HER2-overexpressing metastatic gastric or gastroesophageal junction
adenocarcinoma, who have not received prior treatment for metastatic
disease (1st-line)
Q: Investorideas.com staff:
The Company recently announced in June the FDA approved for
Perjeta in combination with Herceptin- how does this combination improve
results?
A; Nina Goworek, Investor Relations Officer for Roche
The addition of Perjeta in combination with Herceptin plus
docetaxel (chemo) showed an increase of progression free survival (PFS)
from a median of 12.4 months to 18.5 months - an increase of 6.1months.
Statistically significant overall survival top-line results were
announced with the data to be presented at an upcoming medical meeting.
Q: Investorideas.com staff:
What is the current number of women with HER2-positive breast cancer have been treated with Herceptin?
A; Nina Goworek, Investor Relations Officer for Roche
As of January 2012, there were roughly 440,000 patients treated
with Herceptin in the US for all indications and more that 1.2 million
people have been treated with Herceptin globally.
Sunshine Biopharma Inc. (OTCBB: SBFM) and Adva-27a
Q: Investorideas.com
Can you give us a brief history of the development of Adva-27a?
A: Mr. Camille Sebaaly, CFO of Sunshine Biopharma Inc
Adva-27a is a small molecule which we designed and synthesized de
novo. The patents covering Adva-27a and derivatives in the United States
and Europe have issued recently. Various patents in other places around
the world are still pending. Adva-27a was designed to specifically
target multidrug resistant (or aggressive) types of cancer.
Q: Investorideas.com staff
From your recent press releases you now have data on both lung
and breast cancer results for Adva-27a, potentially doubling the market
potential. Can you give investors a brief summary of the results to
date?
A: Mr. Camille Sebaaly, CFO of Sunshine Biopharma Inc.
There are different types of transporter proteins which when
overexpressed make cancer cells resistant to drugs. Different multidrug
resistant cancer types may overexpress different transporter proteins.
Our data to date have shown that Adva-27a can overcome two multidrug
resistance proteins: MDR1 and MRP1 as present in the breast cancer cells
and the lung cancer cells we tested. Lung and breast cancer are the two
most frequently encountered cancers in humans.
Q: Investorideas.com staff
How do your collaborations withthe State
University of New York at Binghamton and McGill University’s Jewish
General Hospital in Montreal ( Canada) help you take Adva-27a to
clinical trials?
A: Mr. Camille Sebaaly, CFO of Sunshine Biopharma Inc
We are delighted for the help, dedication and
contribution
of these two of the finest institutions in the world. They have and
continue to be of great help to us in our efforts to put Adva-27a
through the drug development stages. We anticipate that our first
clinical trial will be done at the Jewish General Hospital on breast
cancer volunteers.
Q: Investorideas.com staff
For investors looking at a small biotech company like yours,
taking on the big pharma companies, how do you address the massive
financial and corporate undertaking of bringing Adva-27a to market?
A: Mr. Camille Sebaaly, CFO of Sunshine Biopharma Inc
It is indeed very costly to bring a drug to market. We have been
fortunate in our financing efforts to date and we hope to be able to
continue to access the private and public markets for funding on an as
needed basis to continue the development of our flagship Adva-27a and
bring it to market for cancer sufferers around the world.
Q: Investorideas.com staff
Do you have any third party projections for the market potential of
Adva-27a?
A: Mr. Camille Sebaaly, CFO of Sunshine Biopharma Inc
We have not commissioned any one to do projections of market
potential of our Adva-27a. However, we do know that important cancer
drugs generally reach annual sales of about $1 billion within 1 to 2
years of FDA approval. We believe Adva-27a will have a similar sales
profile.
About Sunshine Biopharma Inc. (OTCBB: SBFM):
Sunshine Biopharma is a pharmaceutical company focused on the
research, development and commercialization of drugs for the treatment
of various forms of cancer. The Company’s lead compound, Adva-27a
targets aggressive forms of cancer.
www.sunshinebiopharma.com
About Roche (SIX: RO, ROG; OTCQX: RHHBY):
Headquartered in Basel, Switzerland, Roche is a leader in
research-focused healthcare with combined strengths in pharmaceuticals
and diagnostics. Roche is the world's largest biotech company with truly
differentiated medicines in oncology, virology, inflammation,
metabolism and CNS. Roche is also the world leader in in-vitro
diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes
management. Roche's personalized healthcare strategy aims at providing
medicines and diagnostic tools that enable tangible improvements in the
health, quality of life and survival of patients. In 2011, Roche had
over 80,000 employees worldwide and invested over 8 billion Swiss francs
in R&D. The Group posted sales of 42.5 billion Swiss francs.
Genentech, United States, is a wholly owned member of the Roche Group.
Roche has a majority stake in Chugai Pharmaceutical, Japan.
www.roche.com
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector,
including biotech and pharma stocks. Other sectors include renewable
energy, oil and gas, mining and tech stocks.
Visit the biotech portal within Investor Ideas:
www.biotechindustrystocks.com
Follow Investorideas.com on Twitter
http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook
http://www.facebook.com/Investorideas
Sign up for the free investor news and biotech stock alerts
Disclaimer/ Disclosure :
The Investorideas.com is a third party publisher of news and research
Our sites do not make recommendations, but offer information portals to
research news, articles, stock lists and recent research. Nothing on our
sites should be construed as an offer or solicitation to
buy
or sell products or securities. This site is currently compensated by
featured companies, news submissions and online advertising. Disclosure:
A third party on behalf of SBFM compensated Investorideas.com for news
release publishing and distribution: one hundred thousand 144 shares for
three months starting June 26 th
BC Residents and Investor Disclaimer: Effective September 15 2008 -
all BC investors should review all OTC and Pink sheet listed companies
for adherence in new disclosure filings and filing appropriate documents
with Sedar. Read for more info:
http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411
Source -
www.Investorideas.com
Published at Investorideas.com newswire
Learn more about Sunshine Biopharma Inc. (OTCBB:SBFM): Profile
Disclaimer/
Disclosure: The Investorideas.com is a third party publisher of news
and research Our sites do not make recommendations, but offer
information portals to research news, articles, stock lists and recent
research. Nothing on our sites should be construed as an offer or
solicitation to buy or sell products or securities. This site is
currently compensated by featured companies, news submissions and online
advertising. Disclosure: A third party on behalf of SBFM compensates
Investorideas.com for news release publishing and distribution : one
hundred thousand 144 shares for three months starting June 26th
BC Residents and Investor Disclaimer: Effective September 15 2008 -
all BC investors should review all OTC and Pink sheet listed companies
for adherence in new disclosure filings and filing appropriate documents
with Sedar. Read for more info:
http://www.bcsc.bc.ca/release.aspx?id=6894
About IDO Security, Inc. 
Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical
company focused on developing and commercializing products for the
treatment of central nervous system, or CNS, diseases. The company is
developing several product candidates in neurology and psychiatry to
address large market opportunities in epilepsy and ADHD including ADHD
patients with impulsive aggression. These product candidates include
Trokendi XR (extended-release topiramate), formerly known as SPN-538,
and SPN-804 (extended-release oxcarbazepine) for epilepsy, SPN-810 for
impulsive aggression in ADHD and SPN-812 for ADHD.
About Fuel Tech 
About CSR 
About Biofuel Energy 
About Alnylam Pharmaceuticals 
About EMCORE